The special position of intellectual property rights in the global pharmaceutical industry

Intellectual property (IP) rights, especially patents, hold a unique and irreplaceable position in the global pharmaceutical and life sciences industries. This importance stems not only from the legality but also deeply ingrained in the industry's core business model, where huge research and development (R&D) costs come with a high risk of failure.

The need for IP protection in this area is an obvious one, as the technology involved is becoming increasingly complex, opening up many new avenues for creators to protect their inventions. In this context, patents serve as a key mechanism to ensure exclusivity in the market for a certain period of time.

1. A shield against the risk of losing a huge investment cost

The process of discovering and developing a new drug, from initial idea to licensing and bringing to market, typically lasts more than a decade and costs billions of dollars[1]. The complexity of clinical trials, high failure rates in the development stages, and stringent regulatory requirements create a huge financial and scientific barrier.

Therefore, patents are the highest value "legal certificates", assuring inventors that if they succeed, they will have enough exclusive time to recoup their investment, compensate for previous failures, and reinvest in next-generation R&D. Without strong patent protection, competitors can easily copy the product (often at a significantly lower cost) as soon as the drug is licensed, removing any incentive to invest in original research.

2. IP drives innovation in pharmaceutical technology

The increasing complexity of advanced pharmaceutical technologies has turned IP into a strategic tool to protect not only products but also platform technologies.

Fierce disputes between inventors

The rise of biologics and biosimilars has put patents at the forefront of pharmaceutical litigation. These products now account for the majority of the current generation of "blockbuster" drugs.

Unlike traditional small molecules, biological products are much more complex in terms of structure and manufacturing processes. As a result, IP disputes revolve not only around basic compound patents, but also extend to patents that protect manufacturing processes, cell culture materials, and sophisticated protein variants. This shift makes large-scale patent disputes technically more complex.

In addition, the litigation landscape has also witnessed a continuous increase in the frequency of confrontational disputes between inventors. This reflects stiff competition in advanced biotechnology segments, where leading companies compete on platform technology or next-generation product innovations.

AI-based invention and Gene Editing Technology (CRISPR)

Artificial intelligence (AI) is being rapidly applied in drug discovery and platform technologies. The rapid expansion of AI-based tools has created a constant focus on AI-based inventions.

Debates over patentability for AI-powered or generated inventions are sure to arise before the courts and patent offices in the near future. The determination of inventor status is focusing on human contributions, suggesting that global intellectual property laws are trying to adapt to protect these new creative tools.

Similarly, next-generation technologies such as gene-base editing[2] are still at the forefront of innovation and IP disputes. The approval of new CRISPR-based therapies[3] will inevitably lead to litigation, including disputes surrounding licensing agreements related to CRISPR platform technologies. For these technologies, IP protection is paramount because it defines the underlying ownership of the technological instrument that enables invention,  affecting the entire product development chain in the pharmaceutical industry.  

3. The role of IP in pharmaceutical product lifecycle management

IP is not only a tool for protecting original inventions, but also a mechanism for optimizing product life cycles, extending exclusivity, and shaping global market strategies.

Mechanism for extending the term of a patent 

The development of a drug requires a long time to conduct clinical trials and wait for approval by the regulatory bodies of countries. This significantly reduces the actual monopoly time in the market. Patent term extension mechanisms such as Additional Protection Certificates in Europe or patent term extensions in the United States are set up to compensate for this delay, helping inventors recoup their investment.

However, the search for ways to extend IP monopoly through legal tactics is also under intense scrutiny. For example, the European Commission's decision to abuse split patents to prolong a monopoly on the market has been deemed anti-competitive[4]. This decision could have far-reaching implications for product lifecycle management across Europe, forcing companies to consider anti-competitive risks when formulating IP strategies for their products.  

Patent Bonding System

In major markets such as the United States, IP is directly integrated into the drug marketing licensing process. The patent linking system forces generic manufacturers to address the patent status of the inventor before receiving marketing approval.

In its December 2024 ruling, the U.S. Federal Court of Appeals affirmed that in order to qualify for listing in the FDA's Orange Book, a patent must state at least the approved product's active ingredient (or pharmaceutical ingredient/formulation).[5] The ruling clarifies that "stating the pharmaceutical substance" means that the patent must, at a minimum, include the active ingredient. The decision significantly narrows the types of patents that can be listed in the Book of Cam, limiting the ability of brand-name drug manufacturers to use device-only patents to trigger a 30-month moratorium on competition from generic drugs.  

4. Balancing exclusive patent ownership and public interest

Although IP reinforces commercial monopolies, its role is increasingly being weighed in conjunction with social factors and public interests, especially in the healthcare sector and in emergencies such as epidemics.

Original brand name drugs and preliminary bans

The ability to achieve a preliminary injunction (PI) to prevent the launch of generic/biosimilar drugs is key to product monopoly protection. However, there has been a trend in traditionally PI-friendly jurisdictions, such as Australia, to grant fewer bans.

Courts are applying more scrutiny to plaintiffs' assertions of "irreparable harm." A notable development is the growing awareness of the impact of the public interest factor in equilibrium calculations.

This has led to greater restraint on the part of the plaintiffs in seeking preliminary or final injunctive relief when it comes to "critical medicines". The presence of the public interest factor has altered the balance of interests, forcing patent holders to build a detailed dossier, demonstrating that the issuance of a PI will not cause significant harm to the public.

Drug accessibility

The dispute over intellectual property rights has also been at the center of discussions about access to medicines in developing countries and in global health emergencies such as pandemics. Although pharmaceutical companies justify IP as necessary to fund R&D, regulators and international organizations frequently seek to balance IP protection with mechanisms such as mandatory licensing or patent exemptions to ensure timely supplies of essential medicines in emergencies like the Covid 19 pandemic. This tension between IP and the public interest is a constant driving force shaping global legislation and disputes over intellectual property rights.

In conclusion, for the pharmaceutical industry, IP is the lifeblood of innovation. Patents provide legal stability and certainty in an inherently high-risk business, allowing pharmaceutical invention companies to not only survive, but also continue to create high-end scientific therapies of pharmaceuticals and improve the quality of life worldwide.